Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Bradley McGregor MD

Bradley A McGregor MD

Clinical Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA

Dr. Bradley A. McGregor is currently a Medical Oncologist specializing in genitourinary malignancies at the Dana-Farber Cancer Institute. Completing his undergraduate and medical school education at Tufts University; he then joined the United States Air Force at the San Antonio Uniformed Services Health Education Consortium.   He served in Afghanistan as the Deputy Commander for the NATO led Medical Training Advisory Group where he mentored the Afghan physicians.  Reaching the rank of Lieutenant Colonel and receiving the Meritorious Service medal, Dr McGregor left the Air Force in July of 2016 and came to Dana Farber.  A senior physician, he has served as the Clinical Director of the Lank Center for Genitourinary Oncology at DFCI since 2016.  He has served as principal investigator for several trials while leading IITs in treatment of rare genitourinary malignancies, non-clear cell renal cell carcinoma.

Disclosures

Dr. McGregor reports the following disclosures: 

BAM discloses payment for consulting with Bayer, Astellas, Astra Zeneca, Seattle Genetics, Exelixis, Nektar, Pfizer, Janssen, Genentech, Eisai , EMD Serono, BMS and Calithera.  He received research support to Dana Farber Cancer Institute (DFCI) from Bristol Myers Squibb, Calithera, Exelixis, Seattle Genetics. 

Recent Contributions to PracticeUpdate:

  1. RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
  2. Renal Masses in a Functionally Solitary Kidney: Next Steps
  3. Renal Masses in a Functionally Solitary Kidney: Adjuvant Therapy
  4. Atezolizumab and Bevacizumab for Renal Cell Carcinoma With Variant Histology
  5. Durvalumab as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer
  6. Enfortumab Vedotin in the Management of Urothelial Carcinoma
  7. Circulating Tumor DNA in Advanced Urothelial Carcinoma
  8. Updated Perspective on Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma
  9. Quality of Life Among Patients With Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin
  10. Current Perspectives on Non–Clear Cell RCC

Most Read This Week

Recently Updated